Collaborations, Clinical Study Results, and Laboratory Inspection Clearance - Analyst Notes on Amgen, Regeneron, Lexicon, WuXi PharmaTech and ImmunoGen

NEW YORK, June 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4088-100free.

--
Amgen, Inc. Analyst Notes
On June 16, 2014, Amgen, Inc. (Amgen) announced that it will collaborate with the National Cancer Institute (NCI) and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a new clinical program that will use biomarker- driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on individual cancer profiles. The Company stated that in the said trial approximately 500 to 1,000 patients will be screened for more than 200 cancer-related genes. The Company informed that five investigational drugs were selected for inclusion in the initial trail, which includes Amgen's rilotumumab. The Company noted that Lung cancer is the leading cause of death in the US and the most common form of lung cancer, are squamous cell carcinomas. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen said, "This latest collaboration can significantly speed our understanding of targeted approaches for this complex and underserved form of lung cancer, while demonstrating how genomic testing can drive the evolution of clinical trial design." The full analyst notes on Amgen are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/AMGN/report.pdf

--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On June 12, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who responded inadequately to methotrexate (MTX) therapy. According to the Company, the study, called SARIL-RA-MOBILITY, enrolled 1,197 patients who were randomized to three treatment groups dosed subcutaneously every other week, sarilumab 150 mg, sarilumab 200 mg, or placebo all in combination with MTX. The Company informed that both groups demonstrated improvement in disease signs and symptoms of RA at 24 weeks, physical function at 16 weeks, and inhibition of joint damage progression at 52 weeks, thus meeting all three co-primary endpoints. Regeneron stated that both Sarilumab groups also showed improvement on the major clinical response secondary endpoint: defined as reduced signs and symptoms of RA by 70% for at least 24 weeks. The full analyst notes on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/REGN/report.pdf

--
Lexicon Pharmaceuticals, Inc. Analyst Notes
On June 14, 2014, Lexicon Pharmaceuticals, Inc. (Lexicon) presented the clinical study results of the LX4211, an oral dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco. According to the Company, the study which involved patients with Type 2 Diabetes with moderate to severe renal impairment, showed that LX4211 significantly reduces postprandial glucose levels in type 2 diabetes. The Company added that it also presented data which showed that LX4211 improved glycemic control in mice with poorly controlled type 1 diabetes and also significantly lowered blood glucose levels in both low dose and high dose groups while reducing hypoglycemia. The full analyst notes on Lexicon are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/LXRX/report.pdf

--
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On June 20, 2014, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that its toxicology facility in Suzhou recently passed, Good Laboratory Practice (GLP) inspection by the FDA with no major observations. The Company informed that the said surveillance was the first FDA GLP inspection in the facility's five years of operation. According to the Company, the inspection lasted five days and included review of numerous processes, as well as audit of four studies. The full analyst notes on WuXi PharmaTech are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/WX/report.pdf

--
ImmunoGen, Inc. Analyst Notes
On June 16, 2014, ImmunoGen, Inc. (ImmunoGen) announced its preclinical findings for IMGN779, a potential treatment for acute myeloid leukemia at the 19th Congress of the European Hematology Association (EHA) in Milan, Italy. The Company informed that, the IMGN779, an antibody-drug conjugate (ADC), is designed to target and kill CD33-expressing acute myeloid leukemia (AML) cells, including leukemic stem cells, while leaving out normal cells. According to the findings, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro. Dr. Charles Morris, Executive Vice President and Chief Development Officer, said, "Despite good initial responses to existing therapies, many AML patients relapse, driving the need for new treatment options. We believe the unique profile of IMGN779 will enable the achievement of desired activity with a better tolerability profile than other agents currently used to treat this disease." ImmunoGen informed that at present, the Company is preparing to submit the IMGN779 IND in mid-2015. The full analyst notes on ImmunoGen are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/IMGN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review